Echo IQ maps a clear path to FDA clearance for EchoSolv HF
Echo IQ (ASX: EIQ) has reviewed the US Food and Drug Administration’s (FDA) Not Substantially Equivalent (NSE) determination for EchoSolv HF and identified what it believes is a clear path forward to obtaining clearance, which could potentially be achieved over the coming quarters. This update follows the Company’s earlier ASX announcement on 8 September 2026.
Critically for investors, the FDA raised no concerns regarding the underlying technology or core functionality of EchoSolv HF. The matters cited in the NSE determination relate solely to aspects of statistical analysis supporting the clinical validation of the device.
The Company has engaged regulatory consultants and legal counsel and remains committed to working closely with the FDA to address all cited matters. Echo IQ is actively assessing multiple regulatory pathways and is treating clearance as a priority.
When big ASX news breaks, our subscribers know first
Three regulatory pathways under active assessment
Rather than reacting to a single course of action, Echo IQ is evaluating three distinct pathways to advance EchoSolv HF towards FDA clearance. This reflects the Company’s regulatory flexibility and experience in navigating the US medical device approval process.
-
Administrative appeal of the NSE determination: Echo IQ may challenge the FDA’s scientific and regulatory conclusions regarding the NSE determination. This process also allows the Company to gain further insight into the FDA’s rationale. Timelines are not strictly defined and, in certain circumstances, may be shorter than 90 days. Potential outcomes include the NSE determination being overturned, the FDA reopening its review and potentially granting clearance, or the FDA requesting a 510(k) resubmission with clarity on the matters to be addressed.
-
FDA Ombudsman review: The Company is also considering whether to approach the FDA Ombudsman, which can assist with a procedural review of the NSE determination and support Echo IQ’s clearance application with the FDA review team.
-
New 510(k) submission: A fresh 510(k) submission addressing the cited statistical analysis matters is another viable alternative. This process can be undertaken over the coming quarters and represents a well-understood route to clearance.
What is a 510(k) clearance and why does it matter for investors?
The FDA’s 510(k) pathway is a premarket submission process through which a medical device manufacturer demonstrates that its product is at least as safe and effective as a legally marketed device already available in the US market. It is the standard regulatory route for medical devices seeking FDA clearance ahead of commercial deployment.
An NSE determination means the FDA has not cleared the device at this stage. Importantly, it does not represent a final rejection. The distinction matters: the FDA’s feedback on EchoSolv HF identified no concerns about the device’s technology or how it functions. The issues cited are limited to the statistical methodology used to support the clinical validation, a narrower and more addressable category of concern than a fundamental technology objection.
FDA clearance is commercially significant for Echo IQ for several reasons. It is a prerequisite for US commercial deployment of EchoSolv HF. It is also a condition of the additional A$10 million investment tranche from Pro Medicus Limited, as disclosed in the Company’s forward-looking statements. Investors should note that this tranche remains conditional on FDA clearance being obtained, and there is no guarantee that clearance will be achieved within any particular timeframe, or at all.
The Pro Medicus strategic investment of up to A$20 million was structured as secured convertible notes, with the second A$10 million tranche explicitly tied to FDA clearance of EchoSolv HF, making the regulatory outcome a direct financial trigger for one of Echo IQ’s largest disclosed capital commitments.
Strategic partnerships remain intact
Echo IQ has confirmed there has been no material impact to its existing strategic partner agreements following the regulatory activity. The Company’s partnerships with Advara HeartCare, Mayo Clinic, and Pro Medicus Limited remain in place.
The Mayo Clinic distribution agreement covers more than 80 external partner institutions via the Mayo Clinic Platform, with a potential 6-year term and an automatic renewal clause that positions Echo IQ for rapid commercial deployment across the US hospital network once regulatory clearance is secured.
The Company’s stated position is that it believes there is a clear path forward to obtaining FDA clearance for EchoSolv HF, and that clearance remains achievable under the 510(k) route.
Echo IQ — Company Position
Echo IQ believes there is a clear path forward to obtaining FDA clearance for EchoSolv HF. Clearance remains achievable under the 510(k) route.
Echo IQ has stated it will keep investors and shareholders informed as the regulatory process progresses.
| Pathway | What it involves | Potential outcome | Indicative timeline |
|---|---|---|---|
| Administrative Appeal | Challenge the FDA’s scientific and regulatory conclusions regarding the NSE determination | Determination overturned; review reopened; or resubmission required with clarity on matters to address | Not strictly defined; may be under 90 days in certain circumstances |
| FDA Ombudsman Review | Procedural review of the NSE determination; support for clearance application with FDA review team | Greater clarity on process; strengthened clearance application | Not specified |
| New 510(k) Submission | Fresh submission addressing the statistical analysis matters cited by the FDA | Clearance if cited matters are resolved to the FDA’s satisfaction | Over the coming quarters |
Investment case: technology cleared, path defined
The FDA’s feedback on EchoSolv HF is narrow in scope. No concerns were raised regarding the device’s underlying technology or core functionality, and the matters cited relate specifically to the statistical analysis supporting clinical validation. Echo IQ has identified concrete next steps and is actively pursuing resolution through multiple pathways.
It is also worth noting that EchoSolv AS, the Company’s other product and its flagship offering, is already FDA-cleared. This existing regulatory track record demonstrates Echo IQ’s capability to navigate the FDA clearance process.
Should clearance for EchoSolv HF be obtained over the coming quarters, it could potentially unlock the additional A$10 million investment tranche from Pro Medicus Limited, as referenced in the Company’s forward-looking statements. This outcome remains conditional on FDA clearance and is subject to the risks and uncertainties outlined in the announcement. The Company has affirmed its commitment to US market expansion in cardiology AI, with EchoSolv HF positioned as a key product in that strategy.
Don’t Miss the Next Healthcare Tech Breakthrough on the ASX
Get FREE breaking ASX healthcare and tech news delivered to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of the market. Click the “Free Alerts” button at Big News Blast to receive the moment market-moving announcements hit the ASX.